Fig. 8From: Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosisConstruction and validation of a prognostic model in lung adenocarcinoma (LUAD). A Survival analysis of TP53 mutation. B Nomogram. C, D Prediction curve of 3-year survival and 5-year survival of LUAD patients with NOMO model. E Univariate COX Analysis. F Multivariate COX AnalysisBack to article page